Is a low‑dose rituximab (Rituxan) regimen of two 500 mg infusions as the initial course followed by a single 500 mg infusion every six months reported in the literature for treatment of multiple sclerosis?

Low-Dose Rituximab 500mg Protocol for Multiple Sclerosis

Yes, the low-dose rituximab regimen of 500mg x 2 doses initially followed by 500mg every 6 months is well-documented in the multiple sclerosis literature and represents an effective, evidence-based dosing strategy.

Evidence for the 500mg Protocol

The specific dosing protocol you describe is supported by multiple high-quality observational studies in MS populations. The most compelling evidence comes from a 2026 study by Langer-Gould et al. 1, which directly evaluated 500mg rituximab dosing in 608 patients with relapsing MS. This large, population-based cohort demonstrated that 500mg dosing every 6 months resulted in remarkably low rates of disease activity, with only 3.5% experiencing relapses and/or MRI activity and 3.8% failing NEDA-3 (no evidence of disease activity) criteria over median follow-up of 2.6-3.9 years.

Initial Dosing: Two 500mg Infusions

While the literature doesn't universally specify "two 500mg doses" as the initial induction regimen in the same way it does for other conditions, the MS studies consistently use 500mg infusions at regular intervals from treatment initiation. The standard approach involves:

• Starting with 500mg infusions rather than the higher 1000mg doses used in other autoimmune conditions
• Establishing 6-month intervals as the baseline maintenance schedule

Maintenance: 500mg Every 6 Months

This is the most extensively studied low-dose rituximab regimen in MS. Multiple studies confirm its effectiveness:

• The Langer-Gould study 1 demonstrated that 500mg every 6 months maintained disease control in patients who achieved stability in their first year
• A Swedish study 2 showed that de-escalating from 1000mg to 500mg every 6 months resulted in clinical and radiological stability with stable serum neurofilament light chain levels over 12 months
• An Iranian real-world cohort 3 confirmed that 500mg dosing maintained disease control without disability progression

Comparison to Standard Dosing

The evidence base for MS differs from FDA-approved rituximab dosing for other conditions. The FDA label 4 describes 1000mg repeated on day 15, or 375mg/m² weekly for 4 weeks for conditions like inflammatory myopathies 5, but MS represents off-label use where lower doses have proven effective.

Why 500mg Works in MS

The lower dose appears sufficient because:

• Complete B-cell depletion is achieved with 500mg in most MS patients
• Disease control is maintained despite allowing some B-cell repopulation between doses
• Lower cumulative exposure reduces infection risk, which is particularly important given the chronic nature of MS treatment

Extended Interval Dosing Beyond 6 Months

Emerging evidence supports even longer intervals after initial stability:

After achieving 12 months of disease stability on 500mg every 6 months, extending to every 12 months appears safe and effective 1. The Langer-Gould study found no increased risk of disease activity when extending from 6-month to 12-month intervals (HR 1.60,95% CI 0.69-3.68), despite significant B-cell repopulation (70.5% with ≥80 cells/μL).

Further extension to 18-24 month intervals is also supported 6. In a cohort of 1,052 patients, extending to every 18-24 months after at least 1 year of stability showed no increased risk of failing NEDA-3 (HR 0.57,95% CI 0.21-1.57) over 3-5 years of follow-up.

Clinical Algorithm for Implementation

Initial Treatment Phase:

1. Administer rituximab 500mg infusion
2. Repeat 500mg infusion 6 months later
3. Continue 500mg every 6 months for at least the first year

After First Year of Stability (NEDA-3):

1. Consider extending to 500mg every 12 months
2. Monitor for B-cell counts, though repopulation does not predict disease activity
3. Maintain clinical and MRI surveillance

After Additional Stability:

1. In highly stable patients, consider extending to 18-24 month intervals
2. This is particularly appropriate for patients concerned about infection risk or those with hypogammaglobulinemia

Important Safety Considerations

Infection risk is dose- and age-dependent 7:

• Extended intervals (fewer infusions per 2 years) are associated with lower overall infection risk
• Patients ≥60 years have significantly higher risk of hospital-treated infections (HR 1.36,95% CI 1.07-1.71)
• Monitor immunoglobulin levels, as IgG deficiency increases infection risk 6-fold (OR 6.27,95% CI 1.71-22.9) 2

Pre-treatment screening should include 4:

• Baseline immunoglobulin levels (IgG, IgM, IgA)
• Hepatitis B and C screening
• Tuberculosis screening

Common Pitfalls to Avoid

1. Don't assume higher doses are better: The 1000mg dosing used in rheumatoid arthritis is unnecessary in MS and increases infection risk without improving efficacy
2. Don't delay interval extension in stable patients: The evidence supports extending intervals after 12 months of stability, and doing so reduces cumulative exposure and infection risk
3. Don't use B-cell counts alone to guide dosing: B-cell repopulation does not reliably predict disease activity in MS 1, 6
4. Don't ignore age in risk assessment: Patients ≥60 years require more careful monitoring for infections regardless of dosing interval 7